Somewhat Positive News Coverage Somewhat Unlikely to Affect Masimo (MASI) Share Price

Media headlines about Masimo (NASDAQ:MASI) have been trending somewhat positive recently, Accern reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Masimo earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the medical equipment provider an impact score of 46.0453743307326 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s rankings:

Masimo (MASI) traded down $0.32 during mid-day trading on Thursday, hitting $85.78. The stock had a trading volume of 413,757 shares, compared to its average volume of 378,640. The stock has a market capitalization of $4,430.00, a price-to-earnings ratio of 13.59, a PEG ratio of 3.41 and a beta of 0.72. Masimo has a 1-year low of $69.57 and a 1-year high of $104.71.

Masimo (NASDAQ:MASI) last posted its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.53 by $0.17. The business had revenue of $193.69 million during the quarter, compared to analyst estimates of $189.01 million. Masimo had a return on equity of 22.17% and a net margin of 45.83%. The business’s revenue was up 15.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.52 earnings per share. equities research analysts anticipate that Masimo will post 2.95 earnings per share for the current year.

Several research firms have commented on MASI. Zacks Investment Research upgraded Masimo from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research note on Thursday, November 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $108.00 price objective on shares of Masimo in a research note on Friday, November 3rd. Finally, BidaskClub lowered Masimo from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $97.17.

In related news, Director Steven Barker sold 10,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total value of $900,000.00. Following the completion of the transaction, the director now directly owns 73,249 shares in the company, valued at $6,592,410. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Yongsam Lee sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $89.89, for a total value of $449,450.00. Following the completion of the transaction, the executive vice president now owns 74,000 shares of the company’s stock, valued at $6,651,860. The disclosure for this sale can be found here. Insiders sold 63,074 shares of company stock valued at $5,618,945 over the last 90 days. Company insiders own 13.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this article on another website, it was stolen and reposted in violation of United States and international trademark and copyright laws. The correct version of this article can be accessed at

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply